Latest News - Leo

Thursday, May 04, 2017 | Personnel/Company News, PracticalDermatology.com, PracticalDermatology.com, Atopic Dermatitis , Eczema, Leo

LEO Pharma U.S. Welcomes Judit H. Nyirady as Vice President of Medical Strategy & Scientific Affairs

Judit H. Nyirady, MD, MBA, is the new Vice President of Medical Strategy & Scientific Affairs at LEO Pharma Inc. In this role, she will be responsible for the medical and scientific affairs str…

Read the full story

Friday, July 01, 2016 | Personnel/Company News, Leo, Valeant NJ

Valeant Terminates European Licensing Rights for Brodalumab

Valeant Pharmaceuticals International, Inc.'s affiliate and AstraZeneca have amended Valeant's license for brodalumab, an IL-17 receptor monoclonal antibody under regulatory review for patient…

Read the full story

Tuesday, January 19, 2016 | FDA Approval/Clearance, PracticalDermatology.com, Leo

Psoriasis Treatment Update: Rx Enstilar® Is Here

Enstilar®, the recently approved plaque psoriasis foam, is now available in pharmacies by prescription. Manufactured by LEO Pharma, Inc.,  Enstilar® is a once-daily, alcohol-free …

Read the full story

Wednesday, November 11, 2015 | Acquisitions and Mergers, Leo

LEO Pharma to Acquire Global Dermatology Portfolio from Astellas

LEO Pharma A/S and Japanese pharmaceutical company Astellas Pharma Inc. have entered into an Asset Purchase Agreement under which Astellas will transfer its global dermatology business to LEO Pharma f…

Read the full story

Monday, October 19, 2015 | FDA Approval/Clearance, PracticalDermatology.com, Leo

LEO Pharma Inc. Announces FDA Approval of Enstilar Foam for Plaque Psoriasis

The FDA approved LEO Pharma Inc’s Enstilar for the topical treatment of plaque psoriasis in adults 18 years of age and older. Enstilar is a once-daily, alcohol free foam formulation in a pres…

Read the full story

Monday, July 06, 2015 | Personnel/Company News, Leo

LEO Pharma Inc. Announces New Vice President of Sales

Mitchell Johnson has joined the LEO U.S. Region as Vice President of Sales. "Mitch is a welcomed addition to our team. He is an energetic sales leader and strategist with proven results in the ph…

Read the full story

Wednesday, June 10, 2015 | Phase 3/4 Trials, PracticalDermatology.com, Leo

Investigational Foam May Offer Itch Relief for Psoriasis Patients

An investigational aerosol foam may provide rapid itch relief as well as improvements in itch-related sleep loss for patients with psoriasis, according to new data presented at the recent World Congre…

Read the full story

Friday, May 22, 2015 | Acquisitions and Mergers, Leo

arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions

arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies to treat cancer and severe autoimmune diseases, and LEO Pharma entered into…

Read the full story

Tuesday, January 06, 2015 | Phase 3/4 Trials, PracticalDermatology.com, Leo

LEO Pharma Submits NDA for Aerosol Foam for Psoriasis to FDA

LEO Pharma has submitted a New Drug Application to FDA for calcipotriene/betamethasone dipropionate aerosol foam 0,005%/0,064% for the treatment of psoriasis vulgaris. The novel aerosol foam formul…

Read the full story